GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tribute Pharmaceuticals Canada Inc (OTCPK:TBUFF) » Definitions » EV-to-FCF

Tribute Pharmaceuticals Canada (Tribute Pharmaceuticals Canada) EV-to-FCF : -3.30 (As of May. 04, 2024)


View and export this data going back to . Start your Free Trial

What is Tribute Pharmaceuticals Canada EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Tribute Pharmaceuticals Canada's Enterprise Value is $117.40 Mil. Tribute Pharmaceuticals Canada's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2015 was $-35.55 Mil. Therefore, Tribute Pharmaceuticals Canada's EV-to-FCF for today is -3.30.

The historical rank and industry rank for Tribute Pharmaceuticals Canada's EV-to-FCF or its related term are showing as below:

TBUFF's EV-to-FCF is not ranked *
in the Drug Manufacturers industry.
Industry Median: 22.78
* Ranked among companies with meaningful EV-to-FCF only.

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-04), Tribute Pharmaceuticals Canada's stock price is $0.93. Tribute Pharmaceuticals Canada's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2015 was $-0.106. Therefore, Tribute Pharmaceuticals Canada's PE Ratio for today is At Loss.


Tribute Pharmaceuticals Canada EV-to-FCF Historical Data

The historical data trend for Tribute Pharmaceuticals Canada's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tribute Pharmaceuticals Canada EV-to-FCF Chart

Tribute Pharmaceuticals Canada Annual Data
Trend Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.31 -19.24 -6.07 -4.30 -1.80

Tribute Pharmaceuticals Canada Quarterly Data
Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Tribute Pharmaceuticals Canada's EV-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Tribute Pharmaceuticals Canada's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tribute Pharmaceuticals Canada's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tribute Pharmaceuticals Canada's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Tribute Pharmaceuticals Canada's EV-to-FCF falls into.



Tribute Pharmaceuticals Canada EV-to-FCF Calculation

Tribute Pharmaceuticals Canada's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=117.400/-35.549
=-3.30

Tribute Pharmaceuticals Canada's current Enterprise Value is $117.40 Mil.
Tribute Pharmaceuticals Canada's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2015 adds up the quarterly data reported by the company within the most recent 12 months, which was $-35.55 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tribute Pharmaceuticals Canada  (OTCPK:TBUFF) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Tribute Pharmaceuticals Canada's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.93/-0.106
=At Loss

Tribute Pharmaceuticals Canada's share price for today is $0.93.
Tribute Pharmaceuticals Canada's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2015 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.106.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Tribute Pharmaceuticals Canada EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Tribute Pharmaceuticals Canada's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Tribute Pharmaceuticals Canada (Tribute Pharmaceuticals Canada) Business Description

Traded in Other Exchanges
N/A
Address
Tribute Pharmaceuticals Canada Inc was incorporated under the Business Corporations Act (Ontario) on November 14, 1994. The Company is a specialty pharmaceutical company. It conducts acquisition, licensing, development and promotion of healthcare products in Canada. It sells Uracyst and NeoVisc internationally through a number of strategic partnerships. The Company's portfolio of assets includes nine product lines, eight of which are on the market in Canada, including: NeoVisc, NeoVisc Single Dose, Uracyst, BladderChek, Bezalip SR, Soriatane, Cambia, Daraprim, Collatamp G, and MycoVa. The Company markets its products in Canada through its own sales force and currently has licensing agreements for the distribution of select products in over 20 countries, and continues to expand this footprint. It faces product competition from companies marketing competing pharmaceutical products and medical devices in Canada. The Company's operations are or may be subject to various federal, provincial, state and local laws, regulations and recommendations relating to the marketing of products and relationships with treating physicians, data protection, safe working conditions, laboratory and manufacturing practices, the export of products to certain countries and the purchase, storage, movement, use and disposal of hazardous or potentially hazardous substances.
Executives
John M Gregory director, 10 percent owner
Sj Strategic Investments Llc 10 percent owner
Joan P Gregory other: Member 340 EDGEMONT AVE., SUITE 500, BRISTOL TN 37620
James M Gregory other: Member 340 EDGEMONT AVE., SUITE 500, BRISTOL TN 37620
Susan Gregory other: Member 340 MARTIN LUTHER KING, JR. BLVD, SUITE 200, BRISTOL TN 37620

Tribute Pharmaceuticals Canada (Tribute Pharmaceuticals Canada) Headlines

No Headlines